Effect of Nano-Curcumin in Juvenile Idiopathic Arthritis

INTERVENTION: Intervention 1: Intervention group: In the intervention group, patients with JIA will receive standard JIA treatment (according to the ACR 2019 Guideline) along with 40 mg daily curcumin syrup for 3 months. Intervention 2: Control group: In the control group, patients will receive standard treatment of JIA and the volume equivalent of placebo syrup daily for 3 months. CONDITION: Children with Juvenile Idiopathic Arthritis(JIA). ; Juvenile arthritis PRIMARY OUTCOME: In all patients, the severity of JIA disease will be assessed and recorded at baseline, at the end of the first month and at the end of the third month of treatment using the ACR‐Pedi30 Score. The main factors examined in the ACR‐Pedi30 Score are: 1‐ Physician evaluation of the disease activity (PhGA) 2‐ Evaluation of the patient or parents of the child from their child's health 3‐ Evaluation of joint function 4‐ Number of joints involved 5‐ Number of joints with limitations in Range of motion (ROM) 6‐ ESR measurement. Timepoint: At baseline, at the end of the first month and the end of the third month of treatment. Method of measurement: 1‐ Physician evaluation of the disease activity (PhGA) 2‐ Evaluation of the patient or parents of the child from their child's health 3‐ Evaluation of joint function 4‐ Number of joints involved 5‐ Number of joints with limitations in Range of motion (ROM) 6‐ ESR measurement. INCLUSION CRITERIA: All children between 6 and 16 years old referring to Akbar hospital Rheumatology subspecialty clinic who diagnosed suffering JIA according to ACR Guidline1 Obtain patient/patient's parents informed consent